Edition:
United Kingdom

Loxo Oncology Inc (LOXO.OQ)

LOXO.OQ on NASDAQ Stock Exchange Global Market

233.50USD
18 Jan 2019
Change (% chg)

$0.25 (+0.11%)
Prev Close
$233.25
Open
$233.40
Day's High
$233.53
Day's Low
$233.25
Volume
288,903
Avg. Vol
192,841
52-wk High
$233.90
52-wk Low
$85.32

Select another date:

Tue, Jan 8 2019

Photo

Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy

Eli Lilly said on Monday it will buy Loxo Oncology Inc for $8 billion, an expensive bet on a pipeline of cancer drugs that target rare genetic mutations and the biggest acquisition in the drugmaker's 143-year history. The price represents a 68 percent premium to Loxo's Friday share price close, which some Wall Street analysts said was high for a company with only one drug on the market that it shares with a partner. | Video

Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy

Eli Lilly said on Monday it will buy Loxo Oncology Inc for $8 billion (£6.2 billion), an expensive bet on a pipeline of cancer drugs that target rare genetic mutations and the biggest acquisition in the drugmaker's 143-year history. | Video

UPDATE 5-Lilly makes $8 bln bet on drugs for rare cancers with Loxo Oncology buy

Jan 7 Eli Lilly said on Monday it will buy Loxo Oncology Inc for $8 billion, an expensive bet on a pipeline of cancer drugs that target rare genetic mutations and the biggest acquisition in the drugmaker's 143-year history.

Lilly to buy Loxo Oncology for about $8 bln

Jan 7 Eli Lilly and Co said on Monday it would buy Loxo Oncology Inc for about $8 billion in cash.

German stocks - Factors to watch on Nov. 27

BERLIN, Nov 27 The following are some of the factors that may move German stocks on Tuesday:

Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod

A Loxo Oncology Inc drug shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation has won U.S. approval, the Food and Drug Administration announced on Monday.

UPDATE 3-Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod

Nov 26 A Loxo Oncology Inc drug shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation has won U.S. approval, the Food and Drug Administration announced on Monday.

Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod

Nov 26 A Loxo Oncology Inc drug shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation won U.S. approval on Monday, according to the Food and Drug Administration's website.

Roche takes on Loxo, Bayer in gene-defined cancer class

MUNICH Roche's entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.

Roche takes on Loxo, Bayer in gene-defined cancer class

MUNICH Roche's entrectinib cancer pill was shown to shrink tumours in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.

Select another date: